Masashi Okada

13PUBLICATIONS
7CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 28, 2026
Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents.

|Aug 28, 2025
HDAC Class I Inhibitor Domatinostat Induces Apoptosis Preferentially in Glioma Stem Cells Through p53-Dependent and -Independent Activation of BAX Expression.

Yurika Nakagawa-Saito, Yasufumi Ito, Kazuki Nakamura

|Jul 29, 2025
Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells.

Senri Takenouchi, Yasufumi Ito, Kazuki Nakamura

|Sep 14, 2024
CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells.

Yuta Mitobe, Shuhei Suzuki, Kazuki Nakamura

|Apr 13, 2024
The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.

Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi

|Jan 11, 2024
CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.

Keita Togashi, Shuhei Suzuki, Yuta Mitobe

Pageof 3

Frequent Collaborators

11 joint publications

Yurika Nakagawa-Saito

3 joint publications

Yukihiko Sonoda

3 joint publications

Shuhei Suzuki

1 joint publications

Masahiro Yamamoto